Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 53:1219-1226, doi:10.1016/j.jacc.2008.10.064
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi, Y.
Right arrow Articles by Gotthardt, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shi, Y.
Right arrow Articles by Gotthardt, M.
Related Collections
Right arrowRelated Article

PRE-CLINICAL RESEARCH

Cardiac Deletion of the Coxsackievirus-Adenovirus Receptor Abolishes Coxsackievirus B3 Infection and Prevents Myocarditis In Vivo

Yu Shi, MD, PhD*, Chen Chen, MSc*, Ulrike Lisewski, MSc*, Uta Wrackmeyer, MSc*, Michael Radke, PhD*, Dirk Westermann, MD{dagger}, Martina Sauter, DVM{ddagger}, Carsten Tschöpe, MD{dagger}, Wolfgang Poller, MD{dagger}, Karin Klingel, MD{ddagger} and Michael Gotthardt, MD*,§,*

* Neuromuscular and Cardiovascular Cell Biology, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
{dagger} Department of Cardiology, Charité–Campus Benjamin Franklin, Berlin, Germany
{ddagger} Department of Molecular Pathology, University Hospital Tübingen, Tübingen, Germany; and the
§ Department of Veterinary and Comparative Anatomy, Pharmacology, and Physiology, Washington State University, Pullman, Washington. This study was supported by the DFG SFB TR19. Dr. Shi and Miss Chen contributed equally to this work

Manuscript received July 30, 2008; revised manuscript received September 16, 2008, accepted October 7, 2008.

* Reprint requests and correspondence: Dr. Michael Gotthardt, Max-Delbrück-Center for Molecular Medicine Berlin-Buch, Robert-Rössle-Strasse 10, 13125 Berlin, GermanyVCAPP, Washington State University, Wegner Hall, Room 205, Pullman, Washington 99164-6520 (Email: gotthardt{at}vetmed.wsu.edu).

Objectives: We investigated the role of the Coxsackievirus-adenovirus receptor (CAR) in viral myocarditis.

Background: CAR is involved in virus uptake into various cell types. It has therefore been suggested as a therapeutic target to prevent or treat Coxsackievirus B3 (CVB3)-induced diseases such as myocarditis and cardiomyopathy. Recent work in CAR-deficient animals has indicated a role in embryonic development and remodeling with cardiac malformation and lethality.

Methods: We generated a tamoxifen-inducible knockout (KO) mouse to study CAR in the adult heart after CVB3 infection. Histomorphology, virus distribution, and cardiac function were compared in CAR-KO versus noninduced littermate control animals expressing wild-type CAR (WT).

Results: We have demonstrated that eliminating CAR prevents signs of inflammatory cardiomyopathy, with essentially no pathology in KO hearts. Unlike CVB3-infected WT control animals, the cardiac inducible KO mice did not exhibit structural changes such as monocyte infiltration or fibrosis after CVB3 infection or increased production of markers of inflammation such as interleukin-6 and -10. Whereas CVB3 infection resulted in severe contractile dysfunction in the hearts of animals that express WT, the CAR-deficient hearts appeared normal.

Conclusions: Elimination of CAR in adult hearts can efficiently block virus entry and the associated pathology including contractile dysfunction. The lack of infiltration or other morphological changes in CVB3-infected KO hearts emphasizes the contribution of direct virus-mediated pathology in enteroviral myocarditis.

Key Words: cell adhesion molecules • myocarditis • receptors • viruses

Abbreviations and Acronyms
  CAR = Coxsackievirus-adenovirus receptor
  CVB3 = Coxsackievirus B3
  DAF = decay-accelerating factor
  FAM = carboxyfluorescein
  IL = interleukin
  INF = interferon
  KO = knockout
  LCK = lymphocyte protein tyrosine kinase
  LV = left ventricle/ventricular
  MCM = MerCreMer transgenic
  p.i. = after injection with virus
  TAMRA = carboxy-tetramethy-lrhodamine
  TNF = tumor necrosis factor
  WT = noninduced littermate control animals expressing wild-type Coxsackievirus-adenovirus receptor


Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A25. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Vet PatholHome page

Vet. Pathol., July 1, 2009; 46(4): 784 - 784.
[Full Text] [PDF]


Home page
CirculationHome page
T. Yajima and K. U. Knowlton
Viral Myocarditis: From the Perspective of the Virus
Circulation, May 19, 2009; 119(19): 2615 - 2624.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. U. Knowlton and B.-K. Lim
Viral myocarditis is infection of the heart required?
J. Am. Coll. Cardiol., April 7, 2009; 53(14): 1227 - 1228.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement